Hydrogen Gas Inhalation Attenuates Endothelial Glycocalyx Damage and Stabilizes Hemodynamics in a Rat Hemorrhagic Shock Model.
Journal
Shock (Augusta, Ga.)
ISSN: 1540-0514
Titre abrégé: Shock
Pays: United States
ID NLM: 9421564
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
20
7
2021
Statut:
ppublish
Résumé
Hydrogen gas (H2) inhalation during hemorrhage stabilizes post-resuscitation hemodynamics, improving short-term survival in a rat hemorrhagic shock and resuscitation (HS/R) model. However, the underlying molecular mechanism of H2 in HS/R is unclear. Endothelial glycocalyx (EG) damage causes hemodynamic failure associated with HS/R. In this study, we tested the hypothesis that H2 alleviates oxidative stress by suppressing xanthine oxidoreductase (XOR) and/or preventing tumor necrosis factor-alfa (TNF-α)-mediated syndecan-1 shedding during EG damage. HS/R was induced in rats by reducing mean arterial pressure (MAP) to 35 mm Hg for 60 min followed by resuscitation. Rats inhaled oxygen or H2 + oxygen after achieving shock either in the presence or absence of an XOR inhibitor (XOR-I) for both the groups. In a second test, rats received oxygen alone or antitumor necrosis factor (TNF)-α monoclonal antibody with oxygen or H2. Two hours after resuscitation, XOR activity, purine metabolites, cytokines, syndecan-1 were measured and survival rates were assessed 6 h after resuscitation. H2 and XOR-I both suppressed MAP reduction and improved survival rates. H2 did not affect XOR activity and the therapeutic effects of XOR-I and H2 were additive. H2 suppressed plasma TNF-α and syndecan-1 expression; however, no additional H2 therapeutic effect was observed in the presence of anti-TNF-α monoclonal antibody. H2 inhalation after shock stabilized hemodynamics and improved survival rates in an HS/R model independent of XOR. The therapeutic action of H2 was partially mediated by inhibition of TNF-α-dependent syndecan-1 shedding.
Sections du résumé
BACKGROUND
Hydrogen gas (H2) inhalation during hemorrhage stabilizes post-resuscitation hemodynamics, improving short-term survival in a rat hemorrhagic shock and resuscitation (HS/R) model. However, the underlying molecular mechanism of H2 in HS/R is unclear. Endothelial glycocalyx (EG) damage causes hemodynamic failure associated with HS/R. In this study, we tested the hypothesis that H2 alleviates oxidative stress by suppressing xanthine oxidoreductase (XOR) and/or preventing tumor necrosis factor-alfa (TNF-α)-mediated syndecan-1 shedding during EG damage.
METHODS
HS/R was induced in rats by reducing mean arterial pressure (MAP) to 35 mm Hg for 60 min followed by resuscitation. Rats inhaled oxygen or H2 + oxygen after achieving shock either in the presence or absence of an XOR inhibitor (XOR-I) for both the groups. In a second test, rats received oxygen alone or antitumor necrosis factor (TNF)-α monoclonal antibody with oxygen or H2. Two hours after resuscitation, XOR activity, purine metabolites, cytokines, syndecan-1 were measured and survival rates were assessed 6 h after resuscitation.
RESULTS
H2 and XOR-I both suppressed MAP reduction and improved survival rates. H2 did not affect XOR activity and the therapeutic effects of XOR-I and H2 were additive. H2 suppressed plasma TNF-α and syndecan-1 expression; however, no additional H2 therapeutic effect was observed in the presence of anti-TNF-α monoclonal antibody.
CONCLUSIONS
H2 inhalation after shock stabilized hemodynamics and improved survival rates in an HS/R model independent of XOR. The therapeutic action of H2 was partially mediated by inhibition of TNF-α-dependent syndecan-1 shedding.
Identifiants
pubmed: 32804466
doi: 10.1097/SHK.0000000000001459
pii: 00024382-202009000-00014
pmc: PMC7458091
doi:
Substances chimiques
Syndecan-1
0
Hydrogen
7YNJ3PO35Z
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
377-385Références
Redox Biol. 2013 Jun 10;1:353-8
pubmed: 24024171
Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2247-56
pubmed: 16399871
Circulation. 2016 Sep 20;134(12):883-94
pubmed: 27489254
Surgery. 2002 Jan;131(1):50-8
pubmed: 11812963
Shock. 2016 Oct;46(4):352-7
pubmed: 27082315
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
J Biochem. 1994 Jul;116(1):1-6
pubmed: 7798166
Am J Physiol Heart Circ Physiol. 2016 Jun 1;310(11):H1468-78
pubmed: 27037369
Br J Pharmacol. 1998 Aug;124(8):1587-90
pubmed: 9756372
Am J Physiol Heart Circ Physiol. 2000 Dec;279(6):H2815-23
pubmed: 11087236
Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):653-8
pubmed: 14704275
Intensive Care Med Exp. 2016 Dec;4(1):6
pubmed: 26940500
Biochim Biophys Acta. 2014 Sep;1842(9):1502-17
pubmed: 24882753
Crit Care. 2017 Jun 29;21(1):160
pubmed: 28659186
Pflugers Arch. 2007 Jun;454(3):345-59
pubmed: 17256154
FEBS J. 2013 May;280(10):2320-31
pubmed: 23384311
Nat Med. 2012 Aug;18(8):1217-23
pubmed: 22820644
Ann Biomed Eng. 2012 Apr;40(4):840-8
pubmed: 21984514
Curr Opin Lipidol. 2005 Oct;16(5):507-11
pubmed: 16148534
Eur J Pharmacol. 2016 Jun 5;780:224-31
pubmed: 27038523
J Trauma Acute Care Surg. 2017 Mar;82(3):605-617
pubmed: 28225743
Crit Care. 2017 Feb 9;21(1):25
pubmed: 28179016
Microvasc Res. 2013 Jan;85:128-33
pubmed: 23154280
Am J Physiol. 1994 Apr;266(4 Pt 2):H1512-5
pubmed: 8184928
J Trauma Acute Care Surg. 2017 Sep;83(3):469-475
pubmed: 28640781
Pflugers Arch. 2000 Sep;440(5):653-66
pubmed: 11007304
Acute Med Surg. 2017 Oct 24;5(2):113-118
pubmed: 29657720
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jan 1;1008:189-197
pubmed: 26673227
Microvasc Res. 2013 Nov;90:80-5
pubmed: 23899417
Cardiovasc Res. 2010 Jul 15;87(2):300-10
pubmed: 20462866
Ann Biomed Eng. 2012 Apr;40(4):828-39
pubmed: 22009311
Ann Surg. 2011 Aug;254(2):194-200
pubmed: 21772125
Br J Clin Pharmacol. 2015 Sep;80(3):389-402
pubmed: 25778676
Sci Rep. 2016 Jan 07;6:18971
pubmed: 26739257
Anesth Analg. 2011 Jun;112(6):1289-95
pubmed: 21346161
Shock. 2016 Apr;45(4):338-48
pubmed: 26513707
Am J Physiol. 1995 Dec;269(6 Pt 2):H1833-42
pubmed: 8594890
Shock. 2017 Sep;48(3):340-345
pubmed: 28107214
Front Pharmacol. 2019 Feb 19;10:98
pubmed: 30837873
Biochem J. 1993 Dec 15;296 ( Pt 3):803-9
pubmed: 8280080
Curr Vasc Pharmacol. 2016;14(2):187-95
pubmed: 26638794